Pharma Start and H2O Clinical to Merge
Combination of contract research organizations (CROs) to the pharmaceutical and medical device industries will build on existing close collaboration
Hunt Valley, MD and Northbrook, IL – Two leading contract research organizations (CROs) to the pharmaceutical industry, H2O Clinical, based in Hunt Valley, Maryland and Northbrook, Illinois-based Pharma Start, today announced their plan to merge. The companies, which provide a range of outsourced research services to the pharmaceutical industry, already have a history of close collaboration. Each company will continue to operate as it has in the past, and there will be no disruption to current operations or customer contracts.
The combined companies will provide full-service CRO services in biostatistics, data management, clinical operations and medical writing, as well as other ancillary services to the pharmaceutical, medical device and biotechnology industries.
“H2O and Pharma Start already have a very collaborative relationship,” said Eugenia Henry, President of H2O Clinical. “It made perfect sense to build on this strong and successful relationship by combining forces to grow our businesses in complementary areas.” Earl Henry, Chief Medical Officer at H2O Clinical, added, “We’re very excited to offer a full service CRO to the marketplace and our existing clients.”
“The CRO and outsourced pharma contract services market are expected to continue to grow over the next several years,” said Chrissy Fleming, President of Pharma Start. “This growth is a reflection of the ongoing increase in R&D spending around the world and the growth in outsourcing, largely driven by clinical trials becoming more complicated and challenging. Together, Pharma Start and H2O are even more strongly positioned to capitalize on these trends by providing a complete set of premium CRO services to our valued customers.”
About H2O Clinical
H2O Clinical, LLC is a contract research organization focused on data management, statistical programming and biostatistics services in support of pharmaceutical and medical device clinical trials. The Company is based in Hunt Valley, MD. For more information, please visit: www.h2oclinical.com.
About Pharma Start
Pharma Start, based in Northbrook, IL, provides outsourced services, including preclinical assessment, clinical development, clinical pharmacology, translational medicine, medical writing, and regulatory submission and lifecycle management, supporting global pharmaceutical, biotechnology, and medical device companies. For more information, please visit www.pharma-start.com.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
